# US 2023/0056271 A1 · NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERS

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056271 A1
- Document ID: US20230056271A1
- Status: Published application
- Kind: A1
- Application number: 17/654,209
- Filed: 2022-03-09
- Published: 2023-02-23
- Earliest claimed: 2021-03-09
- Assignees: Molecular Partners AG
- Applicants: Molecular Partners AG
- Inventors: Nina RESCHKE; Sebastian GRIMM; Christian REICHEN; Bernd SCHLERETH; Victor LEVITSKY; Matteo BIANCHI
- Web page: https://patentgrep.com/patent/US20230056271A1

## CPC

- A61P 35/02: specific for leukemia
- C07K 16/2809: {against the T-cell receptor (TcR)-CD3 complex}
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- C07K 16/2875: {against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2318/00: Antibody mimetics or scaffolds
- C07K 2318/20: Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
- C07K 2319/00: Fusion polypeptide
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to recombinant multi-specific proteins comprising binding agents with binding specificity for different targets, such as, e.g. CD3, CD33, CD123 and CD70. In addition, the invention relates to nucleic acids encoding such multi-specific proteins, pharmaceutical compositions comprising such proteins or nucleic acids, and the use of such binding proteins, nucleic acids or pharmaceutical compositions in methods for treating or diagnosing diseases, such as cancer, e.g. acute myeloid leukaemia (AML), in a mammal, including a human.

## Claims

### Claim 1

A recombinant protein comprising (1) a first binding agent that specifically binds to a protein expressed on the surface of an immune cell, and (2) at least two binding agents that specifically bind to a tumor-associated antigen, wherein said two binding agents specifically bind to different tumor-associated antigens.

### Claim 2 (depends on 1)

The recombinant protein of claim 1, wherein said protein comprises at least three binding agents that specifically bind to a tumor-associated antigen, wherein said three binding agents specifically bind to different tumor-associated antigens.

### Claim 3 (depends on 1)

The recombinant protein of claim 1, wherein said recombinant protein is capable of binding with a lower dissociation constant (KD) to a surface displaying said tumor-associated antigens, when compared to a recombinant protein comprising only one of said binding agents that specifically bind to a tumor-associated antigen.

### Claim 4 (depends on 3)

The recombinant protein of claim 3, wherein said surface displaying said tumor-associated antigens is the surface of a tumor cell.

### Claim 5 (depends on 1)

The recombinant protein of claim 1, wherein said protein expressed on the surface of an immune cell is CD3.

### Claim 6 (depends on 1)

The recombinant protein of claim 1, wherein said first binding agent is a designed ankyrin repeat domain with binding specificity for CD3.

### Claim 7 (depends on 6)

The recombinant protein of claim 6, wherein said ankyrin repeat domain with binding specificity for CD3 comprises an amino acid sequence that is at least 85% identical to any one of the amino acid sequences of SEQ ID NOs: 1 to 5.

### Claim 8 (depends on 6)

The recombinant protein of claim 6, wherein said ankyrin repeat domain with binding specificity for CD3 comprises any one of the amino acid sequences of SEQ ID NOs: 1 to 5.

### Claim 9 (depends on 1)

The recombinant protein of claim 1, wherein said recombinant protein binds human CD3 in PBS with a dissociation constant (KD) below 10−6M.

### Claim 10 (depends on 1)

The recombinant protein of claim 1, wherein said recombinant protein binds human CD3 with an EC50 ranging from 1 to 400 nM.

### Claim 11 (depends on 1)

The recombinant protein of claim 1, wherein said recombinant protein comprises a polypeptide having an amino acid sequence that is at least 80% identical to anyone of the amino acid sequences of SEQ ID NOs: 11 to 14, 78 to 86 and 95 to 101, preferably wherein said recombinant protein comprises a polypeptide having the amino acid sequence of anyone of SEQ ID NOs: 11 to 14, 78 to 86 and 95 to 101.

### Claim 12 (depends on 1)

The recombinant protein of claim 1, wherein said recombinant protein comprises a polypeptide having an amino acid sequence that is at least 80% identical to anyone of the amino acid sequences of SEQ ID NOs: 95 to 101, preferably wherein said recombinant protein comprises a polypeptide having the amino acid sequence of anyone of SEQ ID NOs: 95 to 101.

### Claim 13 (depends on 1)

The recombinant protein of claim 1, wherein said recombinant protein comprises a polypeptide having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NOs: 95, preferably wherein said recombinant protein comprises a polypeptide having the amino acid sequence of SEQ ID NO: 95.

### Claim 14 (depends on 1)

The recombinant protein of claim 1, wherein said recombinant protein comprises a polypeptide having an amino acid sequence that is at least 80% identical to the amino acid sequence of SEQ ID NOs: 96, preferably wherein said recombinant protein comprises a polypeptide having the amino acid sequence of SEQ ID NO: 96.

### Claim 15 (depends on 1)

The recombinant protein of claim 1, wherein said recombinant protein is capable of binding simultaneously to said protein expressed on the surface of an immune cell, which is specifically bound by said first binding agent, and to said tumor-associated antigens, which are specifically bound by said at least two binding agents that specifically bind to a tumor-associated antigen.

### Claim 16

A recombinant protein comprising a polypeptide having the amino acid sequence of SEQ ID NO: 95 or SEQ ID NO: 96.

### Claim 17 (depends on 1)

A nucleic acid encoding the recombinant protein of claim 1.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the recombinant protein of claim 1, and a pharmaceutically acceptable carrier and/or diluent.

### Claim 19 (depends on 1)

A method of treating a medical condition, the method comprising the step of administering to a patient in need thereof a therapeutically effective amount of the recombinant protein of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein said medical condition is a cancer.
